Critical Analysis: Catalyst Pharmaceuticals (NASDAQ:CPRX) vs. Orion OYJ (OTCMKTS:ORINY)

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Orion OYJ (OTCMKTS:ORINY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Catalyst Pharmaceuticals and Orion OYJ, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0	4	1	3	2.88
Orion OYJ	0	2	1	0	2.33

Catalyst Pharmaceuticals currently has a consensus price target of $32.17, indicating a potential upside of 3.07%. Given Catalyst Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Catalyst Pharmaceuticals is more favorable than Orion OYJ.

Volatility and Risk

Catalyst Pharmaceuticals has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Orion OYJ has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.

Institutional and Insider Ownership

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Catalyst Pharmaceuticals and Orion OYJ’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Orion OYJ	27.14%	50.01%	29.82%

Valuation and Earnings

This table compares Catalyst Pharmaceuticals and Orion OYJ”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99 million	6.48	$214.33 million	$1.74	17.94
Orion OYJ	$2.14 billion	5.02	$566.04 million	$2.18	17.43

Orion OYJ has higher revenue and earnings than Catalyst Pharmaceuticals. Orion OYJ is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Catalyst Pharmaceuticals beats Orion OYJ on 10 of the 14 factors compared between the two stocks.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.